Mid-Term Management Plan Presentation
The 23rd Technology Presentation

from the beginning

Announcement of the Mid-Term Management Plan

Disclaimer

• Our Desired Future State

• Our Business Performance

• Our Strategic Priorities

• Aims of the New Mid-Term Management Plan

Mid-term Management Plan Briefing Session

• Index

1. Review of the Previous Mid-Term Management Plan

• Review of the Previous Mid-Term Management Plan (by Business, Field and Destination)

• Review of the Previous Mid-Term Management Plan

2. Business Environment Assessment and Background of the New Mid-Term Management Plan

• Turning Sysmex's strengths into Tangible Growth Opportunities

• Four Strategic Themes

3. Strategic Themes

• 1. Strengthening the Competitiveness of the Diagnostics Business (1)

• 1. Strengthening the Competitiveness of the Diagnostics Business (2)

• 1. Strengthening the Competitiveness of the Diagnostics Business (3)

• 1. Strengthening the Competitiveness of the Diagnostics Business (Initiatives in China)

• 2. Advancing Medical DX that leverages the strengths of the diagnostic business

• 2. Advancing Data Utilization

• 3. Improving Profitability through Value Chain Transformation

• Initiatives Toward New Growth Drivers

• Human Capital Strategy

4. Management Goals

• Financial Targets for the Fiscal Year Ending March 31, 2029

• Mid-Term Management Plan: Financial Targets

• Mid-Term Management Plan (Sales by Business, Field, and Destination)

• Materiality

5. Financial & Capital Strategy

• Capital Allocation (Fiscal Years Ending March 31, 2027-2029)

• Improving Capital Efficiency and Financial Strategy

• Shareholder Returns

@

The 23rd R&D Meeting

Disclaimer

• Index

1. Initiatives to Realize the Healthcare Journey

• Sysmex’s Long-Term Vision

• Healthcare Journey and P4 Medicine

• “Data Readiness” for the Realization of P4 Medicine

• Achievements (Initiatives) under the Mid-Term Management Plan (1)

• Achievements (Initiatives) under the Mid-Term Management Plan (2)

• Data Compounding Centered on Technologies and Products

• Themes Covered Today

2. Promotion of Medical DX Utilizing Data

• Creating Value Through Data Utilization

• Sysmex’s Strengths in Medical DX

• Refined Testing (1)

• Refined Testing (2)

• Refined Testing: Key Product Release Plan

• Early Warning Detection (1)

• Early Warning Detection (2)

• Early Detection of Warning Signs for Hematopoietic Malignancies

• Visualization of Population-Level Trends (Public Health)(1)

• Visualization of Population-Level Trends (Public Health)(2)

• Support for Hospital and Laboratory Operations (1)

• Support for Hospital and Laboratory Operations (2)

• Inquiry Response Support

• Document Creation Support

• Image Data Interpretation Support

3. Deepening of Liquid Biopsy Technology“Toward the staging and stratification of Alzheimer's disease”

• “Data Readiness” for the Realization of P4 Medicine

• Deepening of Sysmex’s Liquid Biopsy Technology

• Blood Biomarkers for Alzheimer’s Disease

• Development Status of Therapeutic Drugs and Blood-Based Diagnosis

• Status of Blood Biomarker Utilization (U.S. Commercial labs)

• R&D of Disease-Modifying therapies and Utilization of Blood Biomarkers

• Towards staging and stratification of Alzheimer's disease (1)

• Towards staging and stratification of Alzheimer's disease (2)

• Amyloid Pathology-Based Stratification Using HISCLTM Aβ42/40*

• Amyloid Pathology-Based Stratification Using HISCL p-tau217

• Early Detection of Amyloid Pathology in a Healthy Cohort

• Towards staging and stratification of Alzheimer's disease

• p-tau205 and MTBR-tau243

• Development of the HISCL p-tau205 Reagent

• Development of the HISCL MTBR-tau243 Reagent

• Perspective of Technological development for IVD

Initiatives Targeting Regenerative and Cellular Medicine

• Three Pillars of the Regenerative and Cellular Medicine Business

• Regenerative Medical Product Pipeline

• Environment Surrounding Liver Transplants

• Global trends in the reduction and discontinuation of immunosuppressive therapy in organ transplantation

• Inducible inhibitory T-Cells (Investigator-Initiated Clinical Trial Underway)

• Progress of the JB-101 Investigator-Initiated Clinical Trial

• Changes in the Environment Surrounding Regenerative and Cellular Medicine: Automation of Manufacturing Processes

• Concept of an Automated Cell Manufacturing System

• Changes in the Environment Surrounding Regenerative and Cellular Medicine: Quality Control Testing

• Deployment of Our Quality Control Testing

• Development of Rapid Sterility Testing

• Example of Our Quality Control Testing in Practice: Megakaryon (1/2)

• Example of Our Quality Control Testing in Practice: Megakaryon (2/2)

• Open Innovation

Glossary

• Glossary

@